MeSH D008268 - macular degeneration
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
D012162:Retinal degeneration
0 Companies
0 Drugs
Success rate
D008268:
Macular degeneration
D000080362:Stargardt disease
0 Companies
0 Drugs
Success rate
D008269:Macular edema
D057092:Geographic atrophy
0 Companies
0 Drugs
Success rate
D057135:Wet macular degeneration
D057826:Vitelliform macular dystrophy
0 Companies
0 Drugs
Success rate
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| CHEPLAPHARM Arzneimittel | Verteporfin | Visudyne | 2000-07-27 | |||
| Merck & Co | Interferon alfa-2b | Intron A | 1986-06-04 | |||
| Interferon alfa-2b | IntronA | 2000-03-09 | ||||
| Interferon alfa-2b | Viraferon | 2000-03-09 |
Clinical Trials
Historical Success Rate
Phase 1
83%40/48
Phase 2
32%24/75
Phase 3
43%15/35
Approved: 5Overall Success rate: 11%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use